
In the past year, the most exciting development in the field of hematopoietic growth factors has been the identification of the platelet-inducing factor Mpl ligand. Administration of recombinant Mpl ligand may alleviate the potential for hemorrhagic complications following cancer therapies. Stem cell factor continues to be studied clinically in the mobilization of peripheral blood cells for transplantation.

